ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Alemtuzumab Induction Therapy in Elderly Kidney Transplant Recipients.

I. Yakubu,1 B. Masters,1 B. Ravichandran,1 T. Sparkes,1 M. Moss,1 F. Rasetto,1 S. Jonchhe,1 B. Thomas,2 N. Costa,2 D. Leeser,2 S. Bartlett,2 A. Haririan.2

1Pharmacy, University of Maryland Medical Center, Baltimore
2University of Maryland Medical Center, Baltimore.

Meeting: 2016 American Transplant Congress

Abstract number: C38

Keywords: Elderly patients, Induction therapy, Kidney transplantation

Session Information

Date: Monday, June 13, 2016

Session Name: Poster Session C: Clinical Science - Kidney Immunosuppression: Induction Therapy

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Halls C&D

Related Abstracts
  • Alemtuzumab in Elderly Renal Transplant Recipients Is Not Associated With a Poor Outcome
  • The Impact of Alemtuzumab and Basiliximab Induction On Patient and Graft Survival in Single Lung Transplant Recipients

Background: In descriptive studies, alemtuzumab has been associated with an escalating risk of death and graft loss in elderly (≥65 years) kidney transplant recipients. However, this has not been explored in a larger population with a comparator arm. The purpose of this study was to compare the safety and efficacy of alemtuzumab with basiliximab induction in this population.

Methods: This was a retrospective cohort study of kidney transplant recipients ≥65 years old. Patients who received alemtuzumab induction were matched in a 1:2 fashion to the basiliximab control group. Exclusion criteria included multi-organ transplant recipients and patients enrolled in a study protocol. Maintenance immunosuppression consisted of tacrolimus, mycophenolate mofetil and steroids in the majority of patients. The outcomes of interest include patient and graft survival, rate of rejection and infection.

Results: Patient and transplant characteristics are summarized in Figure 1. Post-transplant infections were similar between groups (p=0.08). There was no difference in rates of rejection and infection (p=0.51, p=0.12, respectively). Patient and graft survival rates were also similar (p=0.53, p= 0.14, respectively); with no difference in graft function at any time point during follow-up (p=NS).

Conclusions: Alemtuzumab does not confer additional risk in select elderly renal transplant recipients. Immunologic and infectious risk should be considered when choosing appropriate induction.

CITATION INFORMATION: Yakubu I, Masters B, Ravichandran B, Sparkes T, Moss M, Rasetto F, Jonchhe S, Thomas B, Costa N, Leeser D, Bartlett S, Haririan A. Alemtuzumab Induction Therapy in Elderly Kidney Transplant Recipients. Am J Transplant. 2016;16 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Yakubu I, Masters B, Ravichandran B, Sparkes T, Moss M, Rasetto F, Jonchhe S, Thomas B, Costa N, Leeser D, Bartlett S, Haririan A. Alemtuzumab Induction Therapy in Elderly Kidney Transplant Recipients. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/alemtuzumab-induction-therapy-in-elderly-kidney-transplant-recipients/. Accessed March 2, 2021.

« Back to 2016 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Penis Transplantation: First U.S. Experience.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.